Cellectar Biosciences, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; filed May 12, 2016. Cellectar is a clinical-stage biopharmaceutical company developing phospholipid drug conjugates for cancer treatment and imaging. It reported no product revenue and expects operating losses to continue.
Financial performance and position
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $1.04 million | $1.64 million, down 37% |
| General and administrative expense | $961,000 | $943,000, up 2% |
| Operating loss | $2.00 million | $2.59 million |
| Net income (loss) | $825,000 | $(2.30) million |
| Derivative-warrant revaluation gain | $2.82 million | $288,000 |
| Cash used in operations | $1.82 million | $2.37 million |
| Cash and cash equivalents at period end | $1.91 million | $7.03 million at March 31, 2015 |
| Total liabilities | $2.99 million | $5.95 million at December 31, 2015 |
| Notes payable | $270,000, including current maturities | $330,000 at December 31, 2015 |
| Stockholders’ equity | $2.58 million | $1.65 million at December 31, 2015 |
The reported Q1 net income was driven by a non-cash gain from revaluing warrant liabilities, not operating profitability. The company had an operating loss and used cash in operations. Gross margin and operating margin are not meaningful because the filing reports no revenue.
Material changes and business developments
- R&D expense fell by approximately $605,000, primarily due to lower personnel and travel costs following a 2015 restructuring, costs associated with closure of the glioma trial, reduced SBIR-related costs, and lower facilities expenses. G&A rose modestly, with higher consulting and investor-relations costs partly offset by lower personnel costs.
- On March 4, 2016, the company effected a 1-for-10 reverse stock split. The filing states that Nasdaq notified the company on March 21 that it had regained compliance with the minimum bid-price requirement.
- After quarter-end, the company closed an underwritten offering on April 20, raising approximately $8.0 million gross and $7.2 million net. The offering included common shares and pre-funded and Series A warrants, creating potential dilution.
- After quarter-end, Cellectar agreed to restructure certain 2015 warrants, including exchanging pre-funded warrants for Series Z preferred stock subject to stockholder approval and issuing additional warrants as part of amendments to Series A warrants.
Outlook, risks, and other notable items
- Liquidity and going concern: Management said March 31 cash plus the April offering proceeds was expected to fund operations into 2017, but the filing gives inconsistent estimates: the MD&A says “the first quarter of 2017,” while the risk-factor discussion says “the second quarter of 2017.” The company expects continued losses and needs further financing to execute its plans; additional funding is not assured.
- Pipeline: Lead candidate CLR 131 was in a Phase 1 study for relapsed or refractory multiple myeloma; enrollment was ongoing, with a study update planned for Q3 2016. Other programs described include preclinical therapeutic candidates and imaging assets. These are development-stage programs, and clinical or regulatory success is uncertain.
- Nasdaq listing: The company said the April offering raised pro forma equity above Nasdaq’s $2.5 million minimum and that it believed it had regained equity compliance, while awaiting Nasdaq confirmation. It cautioned that confirmation was not assured.
- Controls: Management concluded disclosure controls and procedures were ineffective as of March 31 because a previously reported material weakness in internal control over financial reporting had not been fully remediated. The weakness involved limited accounting resources and insufficient precision in controls over complex accounting matters. Management stated the financial statements were fairly stated in all material respects.
- Contingencies and related party: The company reported no legal proceedings and did not expect ordinary-course disputes to materially affect the statements. It incurred approximately $71,000 of Q1 expenses with the University of Wisconsin–Madison, where its chief scientific officer is a faculty member and director; approximately $128,000 was accrued at quarter-end.
Important facts for investors to verify
- Whether the April financing runway estimate is through Q1 or Q2 2017, and the assumptions behind it.
- Nasdaq’s final determination on continued listing and equity compliance.
- Progress in CLR 131 enrollment and the timing and substance of the planned clinical update.
- Remediation progress for the material weakness and whether controls over complex transactions become effective.
- The potential dilution and future cash implications of the offering securities and warrant restructuring, including required stockholder approval.